

An Assessment of US Pharmaceutical Donations: Players, Processes, and Products

Edited by Michael R. Reich



**Published by the Harvard School of Public Health
1999**

Boston, MA

Copyright © 1999 by the President and Fellows of Harvard College. All rights reserved

Printed in the United States of America.

ISBN 0-9673960-0-X

Department of Population and International Health
Harvard School of Public Health
665 Huntington Ave.
Building 1, Room 1106
Boston, MA 02115 USA
<http://www.hsph.harvard.edu/reich/donations/>

Table of Contents

Preface	v
1 Introduction and Summary	1
<i>Michael R. Reich</i>	
Introduction	1
Background on the WHO <i>Guidelines</i>	3
Methods	8
Classification of donated drugs	9
Quantitative study	10
Donation policy study	11
Field survey study	12
Main Results	13
Classification of donated drugs	13
Quantitative study	15
Donation policy study	16
Field survey study	17
Discussion	18
2 Classification of Donated Drugs	27
<i>Anita K. Wagner and Frank J. Massaro</i>	
Introduction	27
National EDL Drugs	28
Essential drugs lists	28
The Potential for a “Positive Impact”	30
When donated non-EDL drugs may have a “positive impact”	31
A Classification System of Donated Drugs	32
Application of the classification system	35
The role of the recipient	37
Conclusions and Recommendations	40

3	Quantitative Study	43
	<i>Thomas McLaughlin and Xiaoming Gao</i>	
	Introduction	43
	Methods	44
	Data sources	44
	Analysis	46
	Results	47
	Description of the PVOs	47
	Proportions, frequency, and country recipients of donated products	47
	Analysis of donated products by presence on the WHO Model List of Essential Drugs	51
	Analysis of donated products by time from shipment by the PVO to expiration	52
	Analysis of the effect of dissemination of the WHO <i>Guidelines</i> on trends in time from shipment by PVOs to expiration	61
	Conclusions	61
4	Donation Policy Study	65
	<i>Lisa M. Bates</i>	
	Introduction	65
	Methods	65
	Assessment of Contents	67
	Type of donation program	68
	<i>Rationale</i>	68
	<i>Results</i>	68
	Consignee selection	69
	<i>Rationale</i>	69
	<i>Results</i>	69
	Product selection	72
	<i>Rationale</i>	72
	<i>Results</i>	73
	Communication with consignees	78
	<i>Rationale</i>	78
	<i>Results</i>	78
	Logistics—packaging, labeling, and payment procedures	80
	<i>Rationale</i>	80
	<i>Results</i>	80

Follow-up	81
<i>Rationale</i>	81
<i>Results</i>	82
Assessment of Written Quality and Availability	83
Overall policy availability	83
Quality of written policies and procedures	83
Public availability of policies and procedures	88
Conclusions and Recommendations	88
5 Field Study: Armenia	95
<i>Karin A. Dumbaugh</i>	
Introduction	95
Background on Armenia	95
<i>Important factors affecting drug donations</i>	96
<i>The Armenian healthcare system</i>	98
Limitations of the Field Study	100
The Study Period and the Profile of the Interviewees	101
The health facilities	102
MOH and the Republican Warehouse	102
Other interviewees	103
Description of the Current Donation Process	106
Introduction	106
Regulation of drug donations: role of Ministry of Health	106
<i>The Armenian National Drug Policy</i>	107
<i>The Essential Drugs List</i>	108
<i>The Drug Donation Policy</i>	108
Actors involved and logistics of the shipments	109
<i>Actors involved in MOH</i>	109
<i>Logistics of MOH requests and shipments</i>	112
<i>Donated drugs solicited by institutions</i>	115
<i>Unsolicited drugs sent to institutions</i>	115
Sources and characteristics of the donated drugs	116
<i>The sources of drug donations for health facilities</i>	116
<i>General characteristics of donated drugs</i>	117
<i>Type of drug requested and donated</i>	118
<i>Donated drugs compared with the EDL</i>	123
<i>The expiration of donated drugs</i>	123
<i>Other characteristics of donated drugs</i>	124
<i>Costs of drug donations for the recipients</i>	125

Perceptions of the current drug donation process	
by the recipients	127
Regulations on drug donations	127
Benefits and drawbacks of the current drug donation process	127
<i>Overall perceptions</i>	127
<i>Perceived advantages</i>	128
<i>Perceived drawbacks</i>	131
WHO <i>Guidelines For Drug Donations</i>	133
Knowledge of and reactions to the WHO <i>Guidelines</i>	133
<i>Guidelines perceived as advantageous by ministry officials and facility managers</i>	135
<i>Guidelines perceived as disadvantageous by ministry officials and facility managers</i>	136
<i>Guidelines considered not critical, not possible, irrelevant, or to be decided by the recipient</i>	140
Current and potential impacts of the WHO <i>Guidelines for Drug Donations</i>	140
Conclusions and Recommendations	141
6 Field Study: Tanzania	145
<i>Karin A. Dumbaugh</i>	
Introduction	145
Background on Tanzania	145
<i>Important factors affecting drug donations</i>	146
<i>The Tanzanian healthcare system</i>	148
Limitations of the study	149
The Study Period and Profile of the Interviewees	151
The health facilities	153
The in-country NGOs	154
The Ministry of Health	157
Private pharmacist and drug manufacturer	158
Description of the Current Donation Process	159
Introduction	159
Regulation of drug donations: role of the Ministry of Health	159
<i>The National Health Policy</i>	161
<i>The National Drug Policy</i>	161
<i>The Tanzanian National Essential Drug List</i>	162
<i>The Tanzanian Guidelines on Donations</i>	162

Sources of drug donations, actors involved, and logistics of the shipments	164
<i>Sources of drug donations for healthcare facilities</i>	164
<i>Gifts-in-kind solicited by institutions</i>	164
<i>Donated drugs from abroad through local NGOs: different approaches</i>	166
<i>Unsolicited drugs sent to institutions</i>	169
Characteristics of the donated drugs	170
<i>General characteristics</i>	170
<i>Type of drugs requested and donated</i>	172
<i>Donated drugs compared with the EDL</i>	172
<i>The expiration of donated drugs</i>	173
<i>Other characteristics of the donated drugs</i>	175
<i>Costs of drug donations for the recipients</i>	176
Perceptions of the Current Drug Donation Process by the Recipients	178
Regulations on Drug Donations	178
Benefits and drawbacks of the current drug donation process	179
WHO <i>Guidelines for Drug Donations</i>	179
Knowledge of and reactions to the WHO <i>Guidelines</i>	179
<i>Application</i>	180
<i>Knowledge</i>	180
<i>Reactions to the WHO Guidelines for Drug Donations</i>	181
<i>Guidelines perceived as advantageous</i>	181
<i>Guidelines perceived as unfavorable or of ambiguous benefit</i>	183
Current and potential impacts of the WHO <i>Guidelines</i>	186
Other aspects of donation policies that require improvement	187
Donated drugs preempt local manufacturers	187
Recommendations	187
Recipients' Statements on the Issues	189
Donation process helps	189
The donation process provides free drugs	190
Government regulatory oversight is helpful	190
Perceived drawbacks of the donation process	191
Dependence on undependable donations	192
Insufficient "yield"	192

7 Field Study: Haiti	197
<i>Michèle Derai-Cochin</i>	
Introduction	197
Background on Haiti	197
Limitations of the field study	198
Profile of the Interviewees	199
The health facilities	199
The in-country NGOs	202
The association of NGOs	202
PROMESS	203
The Ministry of Public Health and Population	204
Description of the Current Donation Process	204
Regulations for drug donations: role of MSPP	204
Sources of drug donations, actors involved, and logistics	
of the shipments	205
<i>Health facilities</i>	205
<i>PROMESS</i>	208
<i>In-country NGOs</i>	209
Characteristics of the donated drugs	210
<i>General characteristics</i>	210
<i>Status of the donated drugs with regard to the PROMESS list</i>	211
<i>The shelf life of the donated drugs</i>	216
<i>Other characteristics of the drug donations</i>	217
<i>Costs of drug donations for the recipients</i>	217
<i>The in-country NGOs</i>	219
Perceptions of the Current Drug Donation Process	
by the Recipients	219
Regulations on drug donations	219
Benefits and drawbacks of the current drug donation process	220
<i>Perceived benefits</i>	220
<i>Perceived drawbacks</i>	221
<i>Benefits and drawbacks by source of drugs</i>	223
The WHO Guidelines for Drug Donations	225
Knowledge of and reactions to the WHO <i>Guidelines</i>	225
<i>Reactions to specific WHO Guidelines</i>	225

Potential impacts of the WHO <i>Guidelines</i>	228
<i>Worst-case scenario</i>	228
<i>Best-case scenario</i>	229
Aspects of donation policies that require improvement	229
Conclusions and Recommendations	230
Strengths and weaknesses of the current drug donation process	230
Reactions to the WHO <i>Guidelines</i> and potential impacts	231
Recommendations for improving the drug donation process in Haiti	232
Appendix 1: WHO <i>Guidelines for Drug Donations</i>	235
Appendix 2: PVO-Industry <i>Statement of Principles on the Provision and Distribution of Donated Medicines and Medical Supplies for Disaster and Humanitarian Relief</i>	251
Appendix 3: Drugs Listed as Examples of a Therapeutic Group on the 1995 WHO Model List, and Drugs of Same Group on EDLs of Armenia, Haiti, and Tanzania	255
Appendix 4: Summary of Armenia Field Study	259
Appendix 5: Summary of Tanzania Field Study	265
Appendix 6: Summary of Haiti Field Study	271
Glossary	275
The Authors	279